85
Participants
Start Date
September 1, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
Dermacyte Matrix
The appropriate square centimeters of Dermacyte Matrix is applied directly to the target DFU that is free of debris and necrotic tissue. The Dermacyte Matrix will be applied at weekly intervals or for up to 10 applications.
Standard of Care (SOC)
SOC therapy will consist of debridement of nonviable tissue, saline-moistened non-occlusive dressing, weight off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated at weekly intervals or for up to 10 applications.
Lead Sponsor
Merakris Therapeutics
INDUSTRY